The role of induced pluripotent stem cells in research and therapy of primary immunodeficiencies

Current Opinion in Immunology

Volumn 24, Issue 5, 2012, Pages 617-624

  Weinacht, Katja G ^a   Brauer, Patrick M ^b   Felgentreff, Kerstin ^a   Devine, Alex ^a   Gennery, Andrew R ^c   Giliani, Silvia ^d   Al Herz, Waleed ^e   Schambach, Axel ^f   Zúñiga Pflücker, Juan Carlos ^b   Notarangelo, Luigi D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Sunnybrook Health Sciences Centre   (Canada)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF BRESCIA   (Italy)

^e KUWAIT UNIVERSITY   (Kuwait)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

CELL DIFFERENTIATION; EMBRYONIC STEM CELL; EPIGENETICS; GENE MUTATION; GENE TRANSFER; GENETIC IDENTIFICATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; LYMPHOCYTE HOMING; NUCLEAR REPROGRAMMING; PATHOPHYSIOLOGY; PLURIPOTENT STEM CELL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SOMATIC CELL; T LYMPHOCYTE;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE;

EID: 84867745926     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.07.001     Document Type: Review

References (64)

1. Al-Herz W., Bousfiha A., Casanova J.L., Chapel H., Conley M.E., Cunningham-Rundles C., Etzioni A., Fischer A., Franco J.L., Geha R.S., et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2011, 2:54.
2. Fischer A., Hacein-Bey-Abina S., Cavazzana-Calvo M. Gene therapy for primary adaptive immune deficiencies. J Allergy Clin Immunol 2011, 127:1356-1359.
3. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
4. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., Brugman M.H., Pike-Overzet K., Chatters S.J., de Ridder D., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008, 118:3143-3150.
5. Stein S., Ott M.G., Schultze-Strasser S., Jauch A., Burwinkel B., Kinner A., Schmidt M., Kramer A., Schwable J., Glimm H., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16:198-204.
6. Persons D.A., Baum C. Solving the problem of gamma-retroviral vectors containing long terminal repeats. Mol Ther 2011, 19:229-231.
7. Cooray S., Howe S.J., Thrasher A.J. Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol 2012, 507:29-57.
8. Thomson J.A. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
9. Wilmut I., Schnieke A.E., McWhir J., Kind A.J., Campbell K.H.S. Viable offspring derived from fetal and adult mammalian cells. Nature 1997, 385:810-813.
10. Cowan C.A., Atienza J., Melton D.A., Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005, 309:1369-1373.
11. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
12. Robinton D.A., Daley G.Q. The promise of induced pluripotent stem cells in research and therapy. Nature 2012, 481:295-305.
13. Warlich E., Kuehle J., Cantz T., Brugman M.H., Maetzig T., Galla M., Filipczyk A.A., Halle S., Klump H., Scholer H.R., et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther 2011, 19:782-789.
14. Stadtfeld M., Maherali N., Breault D.T., Hochedlinger K. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008, 2:230-240.
15. Zhao X.Y., Li W., Lv Z., Liu L., Tong M., Hai T., Hao J., Guo C.L., Ma Q.W., Wang L., et al. iPS cells produce viable mice through tetraploid complementation. Nature 2009, 461:86-90.
16. Kim K., Zhao R., Doi A., Ng K., Unternaehrer J., Cahan P., Huo H., Loh Y.H., Aryee M.J., Lensch M.W., et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 2011, 29:1117-1119.
17. Kim K., Doi A., Wen B., Ng K., Zhao R., Cahan P., Kim J., Aryee M.J., Ji H., Ehrlich L.I., et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
18. Sakamoto H., Tsuji-Tamura K., Ogawa M. Hematopoiesis from pluripotent stem cell lines. Int J Hematol 2010, 91:384-391.
19. Nakano T., Kodama H., Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science 1994, 265:1098-1101.
20. Choi K.D., Vodyanik M., Slukvin I.I. Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. Nat Protoc 2011, 6:296-313.
21. Plum J., De Smedt M., Verhasselt B., Kerre T., Vanhecke D., Vandekerckhove B., Leclercq G. Human T lymphopoiesis. In vitro and in vivo study models. Ann N Y Acad Sci 2000, 917:724-731.
22. Coulombel L. Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. Oncogene 2004, 23:7210-7222.
23. Radtke F., Wilson A., Stark G., Bauer M., van Meerwijk J., MacDonald H.R., Aguet M. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999, 10:547-558.
24. Zuniga-Pflucker J.C. T-cell development made simple. Nat Rev Immunol 2004, 4:67-72.
25. Keller G., Kennedy M., Papayannopoulou T., Wiles M.V. Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol Cell Biol 1993, 13:473-486.
26. Salvagiotto G., Burton S., Daigh C.A., Rajesh D., Slukvin I.I., Seay N.J. A defined, feeder-free, serum-free system to generate in vitro hematopoietic progenitors and differentiated blood cells from hESCs and hiPSCs. PLoS ONE 2011, 6:e17829.
27. Choi K.D., Yu J., Smuga-Otto K., Salvagiotto G., Rehrauer W., Vodyanik M., Thomson J., Slukvin I. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 2009, 27:559-567.
28. Dias J., Gumenyuk M., Kang H., Vodyanik M., Yu J., Thomson J.A., Slukvin I.I. Generation of red blood cells from human induced pluripotent stem cells. Stem Cells Dev 2011, 20:1639-1647.
29. Lengerke C., Grauer M., Niebuhr N.I., Riedt T., Kanz L., Park I.H., Daley G.Q. Hematopoietic development from human induced pluripotent stem cells. Ann N Y Acad Sci 2009, 1176:219-227.
30. Raya A., Rodriguez-Piza I., Guenechea G., Vassena R., Navarro S., Barrero M.J., Consiglio A., Castella M., Rio P., Sleep E., et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009, 460:53-59.
31. Feng Q., Lu S.J., Klimanskaya I., Gomes I., Kim D., Chung Y., Honig G.R., Kim K.S., Lanza R. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 2010, 28:704-712.
32. Takayama N., Nishimura S., Nakamura S., Shimizu T., Ohnishi R., Endo H., Yamaguchi T., Otsu M., Nishimura K., Nakanishi M., et al. Transient activation of c-myc expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 2010, 207:2817-2830.
33. Zou J., Sweeney C.L., Chou B.K., Choi U., Pan J., Wang H., Dowey S.N., Cheng L., Malech H.L. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011, 117:5561-5572.
34. Saeki K., Nakahara M., Matsuyama S., Nakamura N., Yogiashi Y., Yoneda A., Koyanagi M., Kondo Y., Yuo A. A feeder-free and efficient production of functional neutrophils from human embryonic stem cells. Stem Cells 2009, 27:59-67.
35. Yokoyama Y., Suzuki T., Sakata-Yanagimoto M., Kumano K., Higashi K., Takato T., Kurokawa M., Ogawa S., Chiba S. Derivation of functional mature neutrophils from human embryonic stem cells. Blood 2009, 113:6584-6592.
36. Morishima T., Watanabe K., Niwa A., Fujino H., Matsubara H., Adachi S., Suemori H., Nakahata T., Heike T. Neutrophil differentiation from human-induced pluripotent stem cells. J Cell Physiol 2011, 226:1283-1291.
37. Slukvin I.I., Vodyanik M.A., Thomson J.A., Gumenyuk M.E., Choi K.D. Directed differentiation of human embryonic stem cells into functional dendritic cells through the myeloid pathway. J Immunol 2006, 176:2924-2932.
38. Silk K.M., Tseng S.Y., Nishimoto K.P., Lebkowski J., Reddy A., Fairchild P.J. Differentiation of dendritic cells from human embryonic stem cells. Methods Mol Biol 2011, 767:449-461.
39. + cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 2005, 105:617-626.
40. Woll P.S., Grzywacz B., Tian X., Marcus R.K., Knorr D.A., Verneris M.R., Kaufman D.S. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 2009, 113:6094-6101.
41. Galic Z., Kitchen S.G., Kacena A., Subramanian A., Burke B., Cortado R., Zack J.A. T lineage differentiation from human embryonic stem cells. Proc Natl Acad Sci USA 2006, 103:11742-11747.
42. Martin C.H., Woll P.S., Ni Z., Zuniga-Pflucker J.C., Kaufman D.S. Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells. Blood 2008, 112:2730-2737.
43. Timmermans F., Velghe I., Vanwalleghem L., De Smedt M., Van Coppernolle S., Taghon T., Moore H.D., Leclercq G., Langerak A.W., Kerre T., et al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J Immunol 2009, 182:6879-6888.
44. Carpenter L., Malladi R., Yang C.T., French A., Pilkington K.J., Forsey R.W., Sloane-Stanley J., Silk K.M., Davies T.J., Fairchild P.J., et al. Human induced pluripotent stem cells are capable of B-cell lymphopoiesis. Blood 2011, 117:4008-4011.
45. Ni Z., Knorr D.A., Clouser C.L., Hexum M.K., Southern P., Mansky L.M., Park I.H., Kaufman D.S. Human pluripotent stem cells produce natural killer cells that mediate anti-hiv-1 activity by utilizing diverse cellular mechanisms. J Virol 2011, 85:43-50.
46. Ye Z., Zhan H., Mali P., Dowey S., Williams D.M., Jang Y.Y., Dang C.V., Spivak J.L., Moliterno A.R., Cheng L. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009, 114:5473-5480.
47. Zou J., Mali P., Huang X., Dowey S.N., Cheng L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011, 118:4599-4608.
48. Sebastiano V., Maeder M.L., Angstman J.F., Haddad B., Khayter C., Yeo D.T., Goodwin M.J., Hawkins J.S., Ramirez C.L., Batista L.F., et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 2011, 29:1717-1726.
49. Agarwal S., Loh Y.H., McLoughlin E.M., Huang J., Park I.H., Miller J.D., Huo H., Okuka M., Dos Reis R.M., Loewer S., et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 2010, 464:292-296.
50. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., Daley G.Q. Disease-specific induced pluripotent stem cells. Cell 2008, 134:877-886.
51. Pessach I.M., Ordovas-Montanes J., Zhang S.Y., Casanova J.L., Giliani S., Gennery A.R., Al-Herz W., Manos P.D., Schlaeger T.M., Park I.H., et al. Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol 2011, 127. 1400-1407 e1404.
52. Mukherjee S., Santilli G., Blundell M.P., Navarro S., Bueren J.A., Thrasher A.J. Generation of functional neutrophils from a mouse model of X-linked chronic granulomatous disorder using induced pluripotent stem cells. PLoS ONE 2011, 6:e17565.
53. Gaspar H.B. Induced pluripotent stem cells and primary immunodeficiencies: a new frontier reached, a new world beyond?. J Allergy Clin Immunol 2011, 127:1408-1409.
54. Silva G., Poirot L., Galetto R., Smith J., Montoya G., Duchateau P., Pâques F. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther 2011, 11:11-27.
55. Urnov F.D., Miller J.C., Lee Y.L., Beausejour C.M., Rock J.M., Augustus S., Jamieson A.C., Porteus M.H., Gregory P.D., Holmes M.C. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005, 435:646-651.
56. Sanjana N.E., Cong L., Zhou Y., Cunniff M.M., Feng G., Zhang F. A transcription activator-like effector toolbox for genome engineering. Nat Protoc 2012, 7:171-192.
57. Porteus M. Homologous recombination-based gene therapy for the primary immunodeficiencies. Ann N Y Acad Sci 2011, 1246:131-140.
58. Hanna J., Wernig M., Markoulaki S., Sun C.W., Meissner A., Cassady J.P., Beard C., Brambrink T., Wu L.C., Townes T.M., Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923.
59. Panopoulos A.D., Belmonte J.C. Induced pluripotent stem cells in clinical hematology: potentials, progress, and remaining obstacles. Curr Opin Hematol 2012, 19:256-260.
60. Notta F., Doulatov S., Laurenti E., Poeppl A., Jurisica I., Dick J.E. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011, 333:218-221.
61. Doulatov S., Notta F., Laurenti E., Dick J.E. Hematopoiesis: a human perspective. Cell Stem Cell 2012, 10:120-136.
62. Mayshar Y., Ben-David U., Lavon N., Biancotti J.C., Yakir B., Clark A.T., Plath K., Lowry W.E., Benvenisty N. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010, 7:521-531.
63. Laurent L.C., Ulitsky I., Slavin I., Tran H., Schork A., Morey R., Lynch C., Harness J.V., Lee S., Barrero M.J., et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011, 8:106-118.
64. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.